Navigation Links
Spherix Announces Annual Shareholders Meeting Date
Date:6/21/2011

BETHESDA, Md., June 21, 2011 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today announced that its Annual Shareholders Meeting, previously scheduled for August 16, 2011, will be held on Tuesday, November 15, 2011, at the Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, Maryland 20817.

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research.  The Company now leverages its scientific and technical expertise and experience through its two subsidiaries -- Biospherics Incorporated and Spherix Consulting, Inc.  Biospherics is dedicated to developing and licensing/marketing proprietary therapeutic products for treatment of diabetes, metabolic syndrome and atherosclerosis.  Biospherics is actively seeking a pharmaceutical partner to continue the development of its Phase 3 compound for the treatment of diabetes, D-tagatose, while exploring new drugs and combinations for treatment of high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke.  Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides.  For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made
'/>"/>

SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Spherix to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
2. Spherix Regains Compliance With NASDAQ Listing Rule
3. Spherix Announces First Quarter Financial Results
4. Spherix Announces Reverse Stock Split Effective May 6, 2011
5. Spherix to Effect Reverse Stock Split
6. Spherix Announces 2010 Financial Results
7. Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference
8. Spherix to Present at the 13th Annual BIO CEO & Investor Conference
9. Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants
10. Spherix to Present at Two Upcoming Prominent Finance Conferences
11. Spherix Phase 2 Trial with D-tagatose Determines Minimum Dose for HbA1c and Triglycerides
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Calif. , May 23, 2013  Saddleback Memorial ... recently became the first hospital on the West ... technology. This new surgical option provides women with a ... Marc Winter , M.D., a ... and surgeon and medical director of minimally invasive surgery ...
(Date:5/23/2013)... May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... DCVax ® personalized immune therapies for solid tumor ... at this year,s American Society Of Clinical Oncology (ASCO) ... its leadership role in immune therapy.  (Logo: ... meeting is the pre-eminent conference focused on clinical treatment ...
(Date:5/23/2013)... , May 23, 2013 Pusan National ... a private biotherapeutics and contract research company focused ... for cancer, announced today a publication reporting the ... with the oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene ... was published in the May 15 th , ...
(Date:5/23/2013)... Louis, Missouri (PRWEB) May 23, 2013 ... and manufacture of complete thermal systems, recently introduced ... than 90 years of experience in designing and ... complete selection of products to serve diverse customer ... options is featured at the beginning of the ...
Breaking Biology Technology:Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3Watlow Introduces Its New Industrial Heater Catalog 2
... IBD with Novel Mode of ActionMOUNTAIN VIEW, Calif., ... announced that data from the company,s PROTECT-1 (the ... Trial) Phase II/III clinical trial of Traficet-EN(TM) (CCX282-B) ... presented in an oral session at the upcoming ...
... Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) ... fiscal year ended February 28, 2009. Neptune reports ... three-month period ended February 28, 2009. Neptune and ... Neptune reports consolidated operating results for its nutraceutical ...
... saves time for reprint buyers by integrating the quote ... Calif., May 19 Reprints Desk, Inc., the content ... Reprints NRx for the Force.com AppExchange from salesforce.com ... the AppExchange is a procurement service that enables buyers ...
Cached Biology Technology:ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 5Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 2Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 3Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 4Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 5Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 2Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 3
(Date:5/21/2013)... known for a long time that some creatures evolve ... particularly for plants. But it may be that height ... University and the U. S. National Evolutionary Synthesis Center. ... May in the journal Nature Communications , Lanfear ... , Drawing from a database of global patterns in ...
(Date:5/21/2013)... considered in the management of natural resources, and ... help them recognize and respond to the relationships ... , Place-Based Conservation: Perspectives from the Social ... Northwest Research Station,s Linda Kruger, can help managers ... is published by Springer Verlag and is available ...
(Date:5/21/2013)... in the body, stem cells in the blood ... into mature immune cells that can fight off ... these cell populations, potentially leading to the development ... a team of researchers led by biologists at ... that, in mouse models, the molecule microRNA-146a (miR-146a) ...
Breaking Biology News(10 mins):Small but speedy: Short plants live in the evolutionary fast lane 2Keeping stem cells strong 2
... This release is available in Spanish . , ... of Radiology and Physical Medicine of the University ... of Public Health (Escuela Andaluza de Salud Pblica), found ... of persistent organic compound (POCs), substances internationally classified as potentially ...
... finds that a chemical found in the body is capable ... in an animal model. The hormone is gastric inhibitory polypeptide ... is a peptide hormone that is secreted in response to ... insulin as part of the digestive process in response to ...
... PITTSBURGH Practice makes perfect or at least thats ... of multiplication tables, goal kicks and piano scales ... many, to be true. Thats why neuroscientists have ... of individual synapses, or connections between neurons, increased, repetitive ...
Cached Biology News:100 percent of people carry at least 1 type of pesticide 2100 percent of people carry at least 1 type of pesticide 3Human hormone blocker found to help prevent obesity and diabetes: study 2Human hormone blocker found to help prevent obesity and diabetes: study 3Novel mechanism for long-term learning identified by Carnegie Mellon researchers 2Novel mechanism for long-term learning identified by Carnegie Mellon researchers 3